Matinas Biopharma (MTNB)
(Delayed Data from AMEX)
$0.70 USD
+0.14 (25.35%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $0.69 -0.01 (-0.82%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMMatinas Biopharma Holdings, Inc. (MTNB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$50.00 | $50.00 | $50.00 | 8,828.57% |
Price Target
Only one analyst offered a short-term price target of $50.00 for Matinas Biopharma Holdings, Inc. This represents an increase of 8% from the last closing price of $0.56.
Analyst Price Targets (1 )
Broker Rating
Matinas Biopharma Holdings, Inc. currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on two recommendations.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 1 | 2 | 3 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 1 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 2.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
11/1/2024 | Alliance Global Partners | James Molloy | Strong Buy | Hold |
10/31/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 2.00 |
# of Recs in ABR | 2 |
Average Target Price | $50.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 75 of 252 |
Current Quarter EPS Est: | NA |